LivaNova PLC filings document the regulatory disclosures of an England and Wales public limited company with ordinary shares listed on Nasdaq under LIVN. Its Form 8-K reports primarily cover operating and financial results, earnings releases, business update calls, material events, and governance changes involving senior officers.
Proxy materials describe annual general meeting procedures, shareholder voting matters, director and governance proposals, and the company’s ordinary share structure. The filings also provide formal records for capital-structure disclosures and corporate governance matters relevant to LivaNova’s medical technology operations in neurological and cardiac conditions.
LivaNova PLC reported stronger results for the quarter ended March 31, 2026, with net revenue of $362.3 million, up 14.3% from the prior-year period. The company generated net income of $22.3 million, compared with a net loss of $327.3 million a year earlier, when it recorded a large SNIA environmental liability charge.
Cardiopulmonary revenue rose 18.3% to $208.7 million, helped by Essenz Perfusion System sales and consumables demand, while Neuromodulation revenue grew 9.3% to $151.8 million on higher implants and pricing. Operating income declined modestly to $41.5 million as research and development spending increased, including expenses tied to ImThera contingent consideration and sleep apnea device development.
The company ended the quarter with cash and cash equivalents of $539.7 million and total debt of $287.8 million after early repaying $95.9 million under its term facilities. LivaNova recorded a current SNIA environmental liability of $389.5 million and a Saluggia site environmental provision of $41.0 million, and noted it believes it has sufficient resources to satisfy the SNIA obligation.
LivaNova PLC reported strong first-quarter 2026 results and raised its full-year outlook. Q1 net revenue was $362.3 million, up 14.3% year over year (11.1% on a constant-currency basis), led by Cardiopulmonary and Neuromodulation growth across all regions.
U.S. GAAP diluted EPS was $0.40 versus a prior-year diluted loss per share of $6.01, which had included a large SNIA environmental charge. Adjusted diluted EPS rose to $0.98 from $0.88. The company generated $15.2 million of net cash from operating activities and $3.8 million of adjusted free cash flow.
LivaNova now expects 2026 revenue to grow 7.0%–8.0% on a constant-currency basis and adjusted diluted EPS of $4.20–$4.30, while maintaining adjusted free cash flow guidance of $160–$180 million. The company also received FDA premarket approval for its aura6000 system for moderate to severe obstructive sleep apnea, positioning it for entry into the OSA market.
LivaNova PLC reports an amended joint Schedule 13G/A disclosing passive shared voting and dispositive interests held by Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander. The filing lists 2,321,067 shares (shared) for Integrated Core Strategies and 2,438,671 shares (shared) for Millennium-related filers, each representing approximately 4.2% and 4.4% of the class respectively.
The filing includes a Joint Filing Agreement dated April 29, 2026 and states these positions are held through entities subject to voting control and investment discretion by Millennium affiliates.
LivaNova PLC is asking shareholders to vote at its virtual 2026 Annual General Meeting on June 10, 2026. Shareholders of record on April 13, 2026, when 54,926,482 Ordinary Shares were in issue, may attend and vote online.
Proposals include electing eleven directors, advisory U.S. and UK say‑on‑pay votes, ratifying PwC in the U.S. and UK, authorizing directors to allot shares up to a nominal £10,985,296, disapplying pre‑emption rights over the same nominal amount, and approving share repurchase contracts covering up to 10% of issued shares. The proxy also details LivaNova’s governance framework, including a largely independent and diverse Board, separate independent Chair and CEO roles, strong committee structure, stock ownership guidelines, and risk, sustainability, and human capital oversight.
LivaNova PLC Chief Innovation Officer Ahmet Tezel reported routine equity compensation changes. Vested restricted stock units converted into 3,408 ordinary shares, with 1,186 shares withheld at $61.27 to cover taxes, leaving 4,157 ordinary shares held directly. Tezel also received 13,873 new restricted stock units and four performance stock unit awards of 4,624 units each, all subject to multi‑year vesting and performance conditions tied to revenue growth, relative total shareholder return, and adjusted earnings per share.
LivaNova PLC executive Franco Poletti, President of Cardiopulmonary, reported routine equity compensation activity involving vested restricted stock units (RSUs) settling into ordinary shares. On March 30, 2026, 3,184 ordinary shares were issued upon RSU vesting, with 1,370 shares withheld at 61.27 per share to cover tax liabilities.
After these transactions, Poletti held 10,755 ordinary shares directly, plus 219 ordinary shares held indirectly through his spouse. The RSUs vested under LivaNova’s 2015 Incentive Award Plan, 2022 Incentive Award Plan and the First Amended and Restated 2022 Incentive Award Plan, reflecting ongoing, scheduled compensation vesting rather than open‑market trading.
LivaNova PLC Chief Financial Officer Alex Shvartsburg reported multiple equity compensation events on March 30, 2026. Vested restricted stock units and performance stock units were settled in ordinary shares, and 30,835 ordinary shares were acquired through exercises. Of these, 12,868 shares were withheld at $61.27 per share to cover tax liabilities, leaving 44,647 ordinary shares held directly afterward.
Earlier performance-based grants vested above target, with awards tied to cumulative free cash flow, return on investment capital, and relative total shareholder return vesting at 122.0%, 118.71%, and 113.89% of target, respectively. New grants included 16,321 restricted stock units and several performance stock unit awards that will vest over future service and performance periods.
LivaNova PLC Chief Executive Officer Vladimir Makatsaria reported multiple equity compensation transactions. On March 30, 2026, vested restricted stock units were settled into 21,042 ordinary shares, increasing his direct holdings to 14,167 ordinary shares after shares were withheld for taxes.
The company withheld 11,159 ordinary shares at $61.27 per share to satisfy tax liabilities. Makatsaria also received new grants of 52,227 restricted stock units and three separate awards of 17,409 performance stock units each, tied to future revenue growth, relative total shareholder return, and adjusted earnings per share over performance periods through 2028.